The use of digitalis has long been plagued by controversy. In the last few years, its efficacy in the prolonged treatment of heart failure among specific groups of patients has been questioned. ' The current controversy stems from a claim by Moss et al. 2 that the use of digitalis may increase mortality among infarction patients with heart failure and complex arrhythmias. Other investigators, [3] [4] [5] on examining their own data, have found no evidence that digitalis is harmful (table 1).
All of these claims, however, have been based not on the results of reliably controlled studies, but on inferences from data bases collected for other purposes. These investigators have used various statistical methods that are purported to overcome the biases arising when observational data are used to assess the effects of treatments. The fundamental problem, of course, is that not only may the treatment affect both the patient's condition and outcome, but conversely various features of the patient's condition may affect the choice of treatment. Features recorded before the institution of a treatment can at least be allowed for in analysis. But unrecorded features cannot be allowed for, and may instead lead to bias and to a mistaken conclusion that a treatment caused a patient's death when in fact it was used because the patient was at risk of death. The classic example is the old joke that, "The most dangerous place in the world is a bed -look at the number of people who die in it!" Some investigators assume that modern statistical methods can circumvent such problems by adjusting for differences in relevant variables. Indeed, if a treatment effect is extremely large, and the biases moderate, careful statistical analysis may lead to correct conclusions. In usual practice, however, only moderate adverse or beneficial effects of treatment are plausible; thus the moderate biases inherent in data-base analyses make it virtually impossible to assess these effects reliably.
Our purpose here is to point out that despite the apparently sophisticated statistical methods used in the published data-base analyses of the effects of digitalis,24 the methodologic approach itself is so inappropriate that any conclusions are subject to great uncertainty. Indeed, both the "data bases" that have been used and those that are that the patients on digitalis were significantly older and smoked more cigarettes, and that more of them had diabetes, angina, previous myocardial infarction, or functional restriction. In addition, during hospitalization, these patients had had a higher incidence of various complications that are indicative of an adverse prognosis, such as congestive heart failure, pulmonary congestion, hypotension, anterior myocardial infarction, tachycardia, ventricular arthythmia, and atrial fibrillation. Not surprisingly, the patients who were given digitalis also received more diuretics and antiarrhythmic agents ( (n =189) (n =783) (n 2600) (n 11,947) (n =585) (n =1014) (n =229) (n =275) (n =250) (n =1671) History (%) with an agent such as digitalis, doctors are likely to be influenced by their assessment of the severity of the disease, and this assessment may well be based on both recorded and unrecorded features. Hence, without randomization some unmeasured, or at least unrecorded, prognostic factors are likely to be unbalanced. Recognition of the possibility that such factors may be importantly related to outcome provided the impetus for the development of randomized clinical trials. Of course, even randomization does not ensure equalization of all risk factors; however, if large numbers of patients are randomized, reasonable comparability of groups is assured, and more importantly, systematic biases are avoided.
The problem of unmeasured prognostic factors, although serious in any observational study, is particularly troublesome in the present context because digitalis is usually prescribed specifically to patients with more severe heart failure. For example, table 1 shows the markedly different characteristics of patients on and off digitalis in the four published studies. Therefore, among the 369 patients with congestive heart failure (CHF) in Moss' study,2 the 95 who were given digitalis by their physicians were likely to have had more severe CHF than the 274 remaining patients. Many of the patients not on digitalis may have had milder heart failure that appeared to be controlled adequately by other means, such as diuretics or salt restriction. Even if one were to try to match these two groups of CHF patients on every known prognostic factor, patients on digitalis are still likely to have been sicker on average than their matched counterparts not on digitalis. Reliance on statistical adjustment here assumes, rather implausibly, that one can reduce the complex medical influences on clinical decisions to a simple function of a few measured variables.
Even if some measure could be recorded for each prognostic factor that might influence the choice of treatment, if these factors were substantially different between treatment groups, covariate adjustment would have severe limitations in assessing treatment effects in retrospective data bases. In any statistical adjustment, investigators initially must assume a theoretical mathematical model describing the form of the relationship between mortality and each of the variables associated with prognosis. The data are used simply to estimate the magnitudes of the relationships presupposed by the model. If the assumed model does not adequately fit the data, then a different model, perhaps suggested by the data, may be used. This iterative spiral continues until model and data fit to the data analyst's satisfaction. The final model is used to adjust the mortality of each disparate treatment group toward a hypothetical common group with baseline characteristics that would fall between the two originally observed groups. Any remaining calculated differences in outcomes between groups are then attributed to treatment.
The method of direct covariate adjustment just described is one of several techniques used to correct for differences in baseline characteristics when comparing two treatments. Two other approaches are the matched case-control design and stratified analysis.8 In many instances, any of these three approaches might be used. However, unlike case-control studies or stratified analysis, regression-type covariate adjustment is technically possible even when the two groups being compared are strikingly dissimilar at baseline. Unfortunately, the fact that a method is technically possible does not endow it with scientific legitimacy. If the groups being compared have so little overlap in characteristics that stratified comparison is either impossible or very difficult, the entire exercise of adjustment for covariates is unreliable.
If the two groups differed only slightly with respect to the measured covariates, then statistical adjustment would tend to correct for these disparities. Even then, random errors in the recorded variables would lead to underadjustment. Thus, in this case, with slightly different groups, statistical models are used to "fine tune" the comparison between treatments. On the other hand, if the groups differ substantially, the adjustment procedure is extremely dependent on the mathematical assumptions. These assumptions cannot be tested effectively because there are little actual data to support what is predicted by the model in the hypothetical middle group. Such is the case in most data-base studies in which one treatment is prescribed to patients who are "'sick" and therefore have an adverse prognosis, for example, those receiving chemotherapy for metastatic cancer and, in this case, digitalis.
Ironically, covariate adjustment is most valid when it is least needed, i.e., when there are no systematic differences (e.g., biases) in prognostic factors between treated and control patients. There is no clear line between cases in which covariate adjustment is acceptable and those in which it is nonacceptable; however, even advocates of historically controlled studies agree that no amount of statistical manipulation can rectify gross imbalances in prognostic features.' In all five studies, the patients on digitalis differ greatly from those not given digitalis with respect to many variables of prognostic importance, and always in the direction of poorer prognosis. Therefore, we strongly believe that covariate adjustment in this case is inappropriate and that such data bases should not be used to test the efficacy or toxicity of digitalis.
Even if the problems relating to adjustment and noncomparability were ignored, the conclusions in Moss et al. would be questionable because the entire excess in mortality was observed in a small subgroup identified after considerable examination of the data. Not surprisingly, this excess was not seen in subsequent studies. The pitfalls of subgroup analysis, even in randomized clinical trials, are well known. 8 Many of the same troublesome methodologic problems apply to the data-base studies that have not found evidence that digitalis is harmful.3' 4 For example, a similar approach to this question was used in an analysis of patients in the Coronary Artery Surgery Study (CASS).3 There, too, large differences in prognostic features and outcomes were noted between patients using digitalis and those not on digitalis. However, after adjustment for several important baseline angiographic and hemodynamic variables (some of which were not available in the study of Moss et al.), the difference in mortality disappeared. Impressive as this may seem, the analysis is subject to the same methodologic difficulties just discussed. Just as Moss' study does not provide good evidence against the use of digitalis, the CASS study should not be interpreted as providing evidence for its safety, although it is reassuring to remember that most of the biases would tend to make digitalis appear worse than it really is. The authors' conclusions were justifiably guarded when they merely stated that the prognostic factors they measured accounted for the apparent effect of digitalis.
Recently, Bigger et al.,6 after reviewing their own data and data from three previous studies, claimed that "pooling" data from all these studies led to the finding of a statistically significant excess of mortality in digitalis-treated patients. The main problem with such an analysis is that "pooling" is only valid when no systematic biases exist in the individual studies.'0 However, in the case of digitalis, "pooling" compounds the biases rather than reinforces the evidence.
Our arguments are not merely about some narrow and arcane theoretical point, but are crucial to the use of data bases to provide reliable evaluations of the effects of many other treatments. When treatments confer large benefits on readily measurable end points, such as direct-current shock for ventricular fibrillation, or when the outcome is invariable without treatment, such as in tuberculous meningitis, formal clinical trials may be unnecessary, for the biases inherent in the less rigorous methodologies, such as use of data bases, historical controls, and simple clinical observations, are likely to be small compared with the observed benefit. On the other hand, controversy about a commonly used treatment usually implies that there is at most a moderate beneficial or adverse effect." In such situations data bases can at best be used to generate hypothesis, rather than to test them. Although correct conclusions may occasionally be drawn from such studies, it is generally impossible to tell whether these inferences are valid or not. Consequently, we believe that only sufficiently large randomized trials can shed adequate light on questions such as the safety and efficacy of digitalis for patients with heart failure, or for that matter, questions regarding many commonly used treatments. The reliable assessment of moderate treatment effects demands that even moderate biases be avoided in making inferences concerning either safety or efficacy.
We therefore believe that the only reliable method of evaluating the effect of digitalis on mortality is by conducting a large randomized study. The feasibility of such a study depends on whether or not currently available alternative treatments are at least equally effective in relieving the symptoms of heart failure. Since the newer vasodilators appear quite effective for symptomatic relief and since symptoms among patients with milder degrees of heart failure can usually be relieved by diuretics alone, such a randomized study may be feasible.
